The increasing desire for semaglutide , innovative therapeutic agent treatments for obesity , has led to considerable difficulties regarding these supply within the USA . Ongoing shortages are stemming from a combination of factors, including manufacturing bottlenecks, substantial individual desire , and involved distribution channels. Consequently